Topic: inflammatory responses

Katalin Karikó and Drew Weissman explain the scientific development of messenger RNA as a therapeutic platform. Their lectures address why laboratory-produced RNA can trigger inflammatory responses and how modification of its nucleosides changes immune recognition and improves protein production. The programme connects those molecular findings with the practical challenges of making RNA stable and delivering it into cells, including lipid-nanoparticle formulations. It follows the development of modified mRNA from a difficult experimental material to a foundation for vaccines and other therapeu

Toll-Like Receptor 4 (TLR4) is a relevant actor for innate immunity involved in inflammatory responses in Multiple Sclerosis (MS) and other diseases. The currently available therapeutic arsenal to treat MS is composed of immunomodulators but, to date, there are no (re)myelinating drugs available in clinics. In the present work, we study the effect of TLR4 inhibition in different animal models of MS.The experimental autoimmune encephalomyelitis (EAE) model was used to evaluate the effect of TLR4 inhibition on reducing the inflammatory component. A more direct effect on oligodendroglia was studi